What Trump’s Expanded Cannabis Access Means for the Industry

A major shift in U.S. drug policy is reshaping how cannabis is regulated, researched, and perceived nationwide. President Trump’s recent executive order reclassifying cannabis from a Schedule I substance to Schedule III represents one of the most significant changes in decades. For businesses working with cannabis financial services, this development introduces new opportunities alongside new compliance responsibilities. While cannabis remains federally illegal, the change signals evolving federal priorities that the industry must understand and prepare for.

What changed under the new executive order?

The executive order directs the U.S. Attorney General to move cannabis into Schedule III of the Controlled Substances Act.

What Schedule III status means

Schedule III substances are defined as having accepted medical uses and a moderate to low potential for physical or psychological dependence. This category includes medications such as ketamine and Tylenol with codeine.

Key implications include:

• Recognition of potential medical value
• Expanded ability to conduct federally approved research
• Reduced classification severity compared to Schedule I

This move represents a clear example of federal cannabis policy changes, even though it stops short of legalization.

What did not change

It is critical for businesses to understand the limits of this shift.

• Cannabis remains illegal at the federal level
• State licensing and regulatory systems still govern operations
• Interstate cannabis commerce is still prohibited
• Federal enforcement authority remains intact

The distinction matters when assessing risk and compliance exposure.

Why this shift matters for the cannabis industry

The reclassification reflects broader momentum toward cannabis regulatory reform, but it also introduces new expectations for operators.

Expanded research and data development

Schedule III status allows health agencies and researchers to study cannabis more freely.

This may lead to:

• Increased clinical trials
• Better understanding of medical benefits and risks
• Stronger data used to guide future regulation

Over time, research findings could influence healthcare adoption and insurance coverage discussions.

Tax implications for cannabis businesses

One of the most immediate business considerations involves taxation.

• Schedule I classification has historically blocked access to key deductions
• Moving to Schedule III may allow relief from restrictive tax provisions
• Improved tax treatment could strengthen margins for compliant businesses

However, implementation timelines remain uncertain.

How expanded access reshapes the regulatory environment

The cannabis business regulatory landscape is becoming more complex rather than simpler.

Increased federal oversight

With reclassification comes deeper federal involvement.

Businesses should expect:

• More attention from health and regulatory agencies
• New reporting and compliance frameworks
• Increased scrutiny of operational practices

These changes will likely roll out gradually through guidance and rulemaking.

State and federal coordination challenges

States continue to regulate cannabis independently.

This creates overlapping obligations:

• State licensing rules remain primary
• Federal classification adds an additional compliance layer
• Conflicts between state and federal guidance may persist

Staying current on cannabis industry compliance updates will be essential.

How the industry is responding

Industry reaction has been mixed, reflecting both optimism and caution.

Support from reform advocates and operators

Many industry groups see the order as validation of long-standing reform efforts.

Supporters point to:

• Recognition of medical legitimacy
• Potential growth in investment and research
• Increased credibility for the industry

They believe the impact of federal cannabis access could unlock new capital and talent.

Resistance from some lawmakers

Not all policymakers support the move.

Concerns raised include:

• Potential normalization of cannabis use
• Questions about long-term health effects
• Worries about impaired judgment and productivity

These debates suggest future reforms will remain incremental rather than sweeping.

What this means for cannabis businesses moving forward

Reclassification does not remove risk, but it changes how risk must be managed.

Operational considerations

Cannabis businesses should prepare for:

• More frequent compliance reviews
• Increased documentation expectations
• Greater transparency across financial operations

Strong internal controls will matter more than ever.

Banking and financial services implications

Financial institutions will continue to act cautiously.

Businesses should expect:

• Ongoing due diligence requirements
• Continued emphasis on documentation and transparency
• Gradual improvement rather than immediate access

The national cannabis legalization outlook remains uncertain, but regulatory momentum is clearly shifting.

How cannabis businesses can prepare now

Preparation should focus on flexibility and compliance.

Practical steps to take

• Monitor federal and state policy developments
• Review compliance processes regularly
• Strengthen financial and HR documentation
• Work with advisors who understand cannabis-specific regulation

Businesses that adapt early will be better positioned as policy evolves.

Why this policy shift matters long term

Although cannabis is still federally illegal, reclassification reflects a broader change in perception.

• Cannabis is increasingly evaluated through a medical framework
• Public support for reform remains strong
• Policy discussions are shifting from ideology to regulation

Over time, these forces may continue to reshape how the industry operates within the U.S. economy.

Who provides cannabis financial services support as regulations evolve?

At Green Leaf Business Solutions, we help cannabis operators stay compliant, organized, and financially prepared as regulations continue to evolve. Our software is built to support accurate payroll, HR, and compliance records that financial institutions expect to see, reducing risk as oversight increases.

 If you want deeper insight into how the hemp industry is responding to new federal product bans, why improved payroll and HR records are critical for staying bank-ready, and what cannabis businesses should know about banking audits in 2025, our team is here to help you navigate every step with confidence. Call today to see how our solutions support long-term stability and growth.